[ad_1]
There are drug candidates Patisiran and Inotersen studied. They seem to slow down the production of proteins that causes the symptoms of skeletal disease. Drabbas, a storage of insoluble protein complexes occurs in body tissues, resulting in impaired function of the heart, nerves and gastrointestinal tract
: Patisiran: 8% of patients improve their ability to walk after 18 months of treatment. says Ole Suhr, lecturer and professor at the University of Umeå
Studies, published in the New England Journal of Medicine, have mainly examined patients with nerve damage. According to Ole Suhr, in Sweden, it is common to affect the heart muscle as an effect of Skelleftesjukan which, according to Ole Suhr, will probably not be able to procure new drugs [19659004]. for approval for Patisiran. About 350 people in Sweden have Skelleftesjukan, most residents around Skellefteå and Piteå.
[ad_2]
Source link
